WDR96 Inhibitors
Chemical inhibitors of WDR96 can function through various mechanisms to impede its activity within cellular processes. Wortmannin and LY294002 are inhibitors targeting the phosphoinositide 3-kinases (PI3K) pathway, which can lead to a reduction in downstream signaling events crucial for the functional utility of WDR96. The suppression of PI3K activity by these inhibitors can result in the attenuation of WDR96's participation in cellular signaling, thus inhibiting its function. Similarly, Staurosporine, a broadly targeting kinase inhibitor, can disrupt multiple phosphorylation-dependent pathways, potentially affecting the kinase activity necessary for WDR96's function. Rapamycin, an inhibitor of the mTOR pathway, can interfere with cell growth and proliferation processes that may involve WDR96, thereby impeding its functional role in these cellular events.
Further, compounds like U0126, SB203580, SP600125, and PD98059 disrupt the MAPK signaling cascade at various points. U0126 and PD98059 specifically target MEK1/2, preventing the activation of ERK, which could be essential for WDR96's operations. SB203580's inhibition of p38 MAPK and SP600125's targeting of JNK can suppress stress response pathways and gene expression regulation, respectively, leading to the functional inhibition of WDR96 by altering the signaling context in which it operates. In another aspect of cellular regulation, Y-27632's selective inhibition of ROCK can impact cytoskeleton organization and cell motility, processes that may be regulated by WDR96, thus affecting its function. Additionally, Bortezomib's role as a proteasome inhibitor can lead to the accumulation of misfolded proteins, inducing a stress environment that could inhibit WDR96 indirectly by impacting the cellular proteostasis. Lastly, ZM-447439, which target Aurora kinases, can interfere with cell division and the cell cycle, thereby affecting WDR96's ability to contribute to these critical cellular functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream of many signaling pathways. Inhibition of PI3K can lead to reduced activity of downstream effectors that may be necessary for WDR96 function, thus functionally inhibiting WDR96 by limiting its signaling capacity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another well-known inhibitor of PI3K. By inhibiting PI3K, LY294002 can decrease the phosphorylation of downstream targets that are potentially critical for WDR96's functional role, thereby inhibiting the function of WDR96 by hampering necessary signaling events. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. WDR96, being a part of the cellular machinery that relies on phosphorylation events, can be functionally inhibited as staurosporine interferes with the kinase activity that is required for WDR96's proper functioning. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mTOR pathway, which is implicated in cell growth and proliferation. Since WDR96 might be involved in these processes, inhibition of mTOR signaling by rapamycin can lead to a functional inhibition of WDR96 by preventing it from participating in these critical cellular functions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. By inhibiting MEK1/2, U0126 can block the activation of ERK, which may be necessary for WDR96's function within the cell, thus functionally inhibiting WDR96 through impaired MAPK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK signaling pathway is involved in stress response and apoptosis. By inhibiting p38 MAPK, SB203580 can disrupt pathways that WDR96 may rely on for its functional role, leading to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathways. JNK is involved in controlling gene expression and cellular stress responses. Inhibition of this kinase by SP600125 can affect pathways that require WDR96's function, thereby functionally inhibiting WDR96. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the activation of MAPK/ERK. By inhibiting MEK and subsequent ERK activation, PD98059 can prevent the phosphorylation of proteins that interact with WDR96, leading to its functional inhibition as the protein is unable to participate in its normal cellular roles. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated protein kinase), which plays a significant role in regulating cytoskeleton organization and cell motility. By inhibiting ROCK, Y-27632 can disrupt cellular processes that WDR96 may be necessary for, thus functionally inhibiting WDR96 by compromising cellular structures and processes it may regulate. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, inducing cellular stress. Since WDR96 is involved in cellular processes that could be sensitive to proteostatic stress, bortezomib’s action can lead to an environment where WDR96 is functionally inhibited due to the inability of the cell to maintain proper protein homeostasis. | ||||||